|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-9-4
|
|
pubmed:abstractText |
The proliferative activity of a tumour is considered to be an important prognostic factor in primary breast cancer. We have investigated the prognostic value of the MIB-1 labelling index in 341 patients with primary breast cancer and compared the results with the S-phase fraction in 220 patients of the same cohort. All patients were treated in one hospital and had a median follow-up of 128 months. No correlation between MIB-1 labelling and S-phase fraction could be demonstrated. MIB-1 had prognostic value for disease-free survival in the whole group of patients (P < 0.001) and in the node-negative subgroup (P < 0.001). In multivariate analysis, MIB-1 was an independent prognostic factor (P = 0.004) besides axillary lymph node status (P = 0.001). In univariate analysis high S-phase fraction was associated with decreased overall survival (P = 0.04); however, not in multivariate analysis. Moreover, S-phase fraction had a borderline prognostic significance for post-relapse survival in multivariate analysis (P= 0.08). Thus, in conclusion, the growth fraction of a tumour as determined by the MIB-1 labelling index is an important prognostic factor in patients with primary breast cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-1453271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-1592381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-1651805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-1709656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-1756257,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-2472168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-2653738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-3967551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-6478442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7562249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7611179,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7633653,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7710989,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7819031,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7865846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7884430,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-7911454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8123870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8394732,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8508358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8518219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8570124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8608982,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8898980,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8911102,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-8944614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-9166949,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-9816101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9716027-9816207
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
460-5
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9716027-Adult,
pubmed-meshheading:9716027-Aged,
pubmed-meshheading:9716027-Antibodies, Monoclonal,
pubmed-meshheading:9716027-Breast Neoplasms,
pubmed-meshheading:9716027-Disease-Free Survival,
pubmed-meshheading:9716027-Female,
pubmed-meshheading:9716027-Flow Cytometry,
pubmed-meshheading:9716027-Humans,
pubmed-meshheading:9716027-Immunohistochemistry,
pubmed-meshheading:9716027-Ki-67 Antigen,
pubmed-meshheading:9716027-Middle Aged,
pubmed-meshheading:9716027-Multivariate Analysis,
pubmed-meshheading:9716027-Prognosis,
pubmed-meshheading:9716027-S Phase
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
MIB-1 labelling index is an independent prognostic marker in primary breast cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, University Hospital Maastricht, The Netherlands.
|
|
pubmed:publicationType |
Journal Article
|
